Nephros, Inc. (NEPH)
USD 1.81
(-2.16%)
USD 1.81
(-2.16%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -2.47 Million USD | 2.75% |
| 2022 | -2.54 Million USD | 56.56% |
| 2021 | -5.85 Million USD | 3.72% |
| 2020 | -6.07 Million USD | -274.83% |
| 2019 | -1.62 Million USD | 36.48% |
| 2018 | -2.55 Million USD | -382.42% |
| 2017 | -529 Thousand USD | -193.96% |
| 2016 | 563 Thousand USD | 145.11% |
| 2015 | -1.24 Million USD | 2.8% |
| 2014 | -1.28 Million USD | -264.83% |
| 2013 | 779 Thousand USD | 1757.45% |
| 2012 | -47 Thousand USD | 97.18% |
| 2011 | -1.66 Million USD | -741.92% |
| 2010 | 260 Thousand USD | 125.9% |
| 2009 | -1 Million USD | 56.46% |
| 2008 | -2.3 Million USD | 13.57% |
| 2007 | -2.66 Million USD | -148.37% |
| 2006 | 5.51 Million USD | 3284.15% |
| 2005 | 162.98 Thousand USD | 104.38% |
| 2004 | -3.71 Million USD | 3.93% |
| 2003 | -3.87 Million USD | -1147.45% |
| 2002 | 369.58 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -1.5 Million USD | 22.04% |
| 2024 Q1 | -1.92 Million USD | 22.14% |
| 2023 Q3 | -3.84 Million USD | -19.95% |
| 2023 Q2 | -3.2 Million USD | -10.26% |
| 2023 Q1 | -2.9 Million USD | -14.33% |
| 2023 FY | -2.47 Million USD | 2.75% |
| 2023 Q4 | -2.47 Million USD | 35.68% |
| 2022 Q1 | -4.45 Million USD | 23.85% |
| 2022 Q3 | -3.36 Million USD | -1.94% |
| 2022 Q4 | -2.54 Million USD | 24.53% |
| 2022 FY | -2.54 Million USD | 56.56% |
| 2022 Q2 | -3.3 Million USD | 25.86% |
| 2021 FY | -5.85 Million USD | 3.72% |
| 2021 Q2 | -6.85 Million USD | -3.96% |
| 2021 Q3 | -6.07 Million USD | 11.38% |
| 2021 Q4 | -5.85 Million USD | 3.69% |
| 2021 Q1 | -6.59 Million USD | -8.51% |
| 2020 Q3 | -2.84 Million USD | 38.55% |
| 2020 Q1 | -6.39 Million USD | -294.2% |
| 2020 Q2 | -4.62 Million USD | 27.62% |
| 2020 Q4 | -6.07 Million USD | -113.79% |
| 2020 FY | -6.07 Million USD | -274.83% |
| 2019 Q2 | -1.11 Million USD | 0.09% |
| 2019 FY | -1.62 Million USD | 36.48% |
| 2019 Q3 | -777 Thousand USD | 30.5% |
| 2019 Q4 | -1.62 Million USD | -108.62% |
| 2019 Q1 | -1.11 Million USD | 56.15% |
| 2018 Q1 | -482 Thousand USD | 8.88% |
| 2018 Q4 | -2.55 Million USD | 37.31% |
| 2018 FY | -2.55 Million USD | -382.42% |
| 2018 Q2 | -2.19 Million USD | -354.98% |
| 2018 Q3 | -4.07 Million USD | -85.64% |
| 2017 Q3 | 1.33 Million USD | 125.89% |
| 2017 Q2 | 591 Thousand USD | 868.85% |
| 2017 Q4 | -529 Thousand USD | -139.63% |
| 2017 FY | -529 Thousand USD | -193.96% |
| 2017 Q1 | 61 Thousand USD | -89.17% |
| 2016 Q1 | -701 Thousand USD | 43.83% |
| 2016 Q3 | 7000.00 USD | 100.86% |
| 2016 Q2 | -811 Thousand USD | -15.69% |
| 2016 FY | 563 Thousand USD | 145.11% |
| 2016 Q4 | 563 Thousand USD | 7942.86% |
| 2015 Q2 | -1.03 Million USD | -182.56% |
| 2015 FY | -1.24 Million USD | 2.8% |
| 2015 Q1 | -367 Thousand USD | 71.42% |
| 2015 Q4 | -1.24 Million USD | 31.16% |
| 2015 Q3 | -1.81 Million USD | -74.83% |
| 2014 Q4 | -1.28 Million USD | -330.52% |
| 2014 Q2 | -225 Thousand USD | 52.43% |
| 2014 Q1 | -473 Thousand USD | -160.72% |
| 2014 FY | -1.28 Million USD | -264.83% |
| 2014 Q3 | 557 Thousand USD | 347.56% |
| 2013 Q4 | 779 Thousand USD | 563.69% |
| 2013 Q3 | -168 Thousand USD | 43.62% |
| 2013 FY | 779 Thousand USD | 1757.45% |
| 2013 Q2 | -298 Thousand USD | -128.19% |
| 2013 Q1 | 1.05 Million USD | 2348.94% |
| 2012 Q2 | -987 Thousand USD | 54.6% |
| 2012 Q3 | -366 Thousand USD | 62.92% |
| 2012 Q4 | -47 Thousand USD | 87.16% |
| 2012 Q1 | -2.17 Million USD | -30.26% |
| 2012 FY | -47 Thousand USD | 97.18% |
| 2011 Q3 | -2.11 Million USD | -23.58% |
| 2011 Q1 | -2.24 Million USD | -964.23% |
| 2011 Q2 | -1.71 Million USD | 23.77% |
| 2011 FY | -1.66 Million USD | -741.92% |
| 2011 Q4 | -1.66 Million USD | 21.16% |
| 2010 Q2 | -344 Thousand USD | 39.01% |
| 2010 Q1 | -564 Thousand USD | 43.82% |
| 2010 FY | 260 Thousand USD | 125.9% |
| 2010 Q4 | 260 Thousand USD | 161.76% |
| 2010 Q3 | -421 Thousand USD | -22.38% |
| 2009 FY | -1 Million USD | 56.46% |
| 2009 Q3 | -1.79 Million USD | -101.69% |
| 2009 Q1 | -1.65 Million USD | 28.4% |
| 2009 Q2 | -890 Thousand USD | 46.09% |
| 2009 Q4 | -1 Million USD | 44.07% |
| 2008 FY | -2.3 Million USD | 13.57% |
| 2008 Q4 | -2.3 Million USD | 38.42% |
| 2008 Q3 | -3.74 Million USD | -166.74% |
| 2008 Q2 | -1.4 Million USD | 43.95% |
| 2008 Q1 | -2.5 Million USD | 6.11% |
| 2007 Q3 | 11.07 Million USD | 117.28% |
| 2007 Q4 | -2.66 Million USD | -124.09% |
| 2007 Q1 | 5.16 Million USD | -6.45% |
| 2007 Q2 | 5.09 Million USD | -1.22% |
| 2007 FY | -2.66 Million USD | -148.37% |
| 2006 Q3 | 4.85 Million USD | 12.31% |
| 2006 Q4 | 5.51 Million USD | 13.71% |
| 2006 FY | 5.51 Million USD | 3284.15% |
| 2006 Q1 | 758.45 Thousand USD | 365.35% |
| 2006 Q2 | 4.31 Million USD | 469.46% |
| 2005 Q3 | 671.05 Thousand USD | 123.82% |
| 2005 Q2 | -2.81 Million USD | 34.72% |
| 2005 FY | 162.98 Thousand USD | 104.38% |
| 2005 Q1 | -4.31 Million USD | -94.45% |
| 2005 Q4 | 162.98 Thousand USD | -75.71% |
| 2004 Q4 | -2.21 Million USD | 76.49% |
| 2004 FY | -3.71 Million USD | 3.93% |
| 2004 Q2 | -3.69 Million USD | 0.0% |
| 2004 Q3 | -9.43 Million USD | -155.29% |
| 2003 FY | -3.87 Million USD | -1147.45% |
| 2002 FY | 369.58 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 2.58 Million USD | 195.738% |
| AngioDynamics, Inc. | -70.14 Million USD | 96.477% |
| AtriCure, Inc. | -9.81 Million USD | 74.827% |
| Avinger, Inc. | 10.12 Million USD | 124.417% |
| Azenta, Inc. | -618.47 Million USD | 99.6% |
| BioLife Solutions, Inc. | 7.25 Million USD | 134.069% |
| The Cooper Companies, Inc. | 2.44 Billion USD | 100.101% |
| Daxor Corporation | 755.65 Thousand USD | 426.999% |
| Ekso Bionics Holdings, Inc. | -1.47 Million USD | -68.095% |
| Femasys Inc. | -15.01 Million USD | 83.543% |
| GlucoTrack, Inc. | -4.29 Million USD | 42.481% |
| Harvard Bioscience, Inc. | 38.49 Million USD | 106.42% |
| Hologic, Inc. | 374.4 Million USD | 100.66% |
| ICU Medical, Inc. | 1.45 Billion USD | 100.17% |
| Intuitive Surgical, Inc. | -2.66 Billion USD | 99.907% |
| KORU Medical Systems, Inc. | -7.03 Million USD | 64.886% |
| LeMaitre Vascular, Inc. | -5.17 Million USD | 52.242% |
| Innovative Eyewear, Inc. | -4.28 Million USD | 42.367% |
| Innovative Eyewear, Inc. | -4.28 Million USD | 42.367% |
| Masimo Corporation | 804 Million USD | 100.307% |
| Microbot Medical Inc. | -2.28 Million USD | -8.093% |
| Meihua International Medical Technologies Co., Ltd. | -9.59 Million USD | 74.249% |
| Merit Medical Systems, Inc. | 302.22 Million USD | 100.818% |
| NovoCure Limited | 355.42 Million USD | 100.695% |
| NEXGEL, Inc. | 98 Thousand USD | 2621.429% |
| NEXGEL, Inc. | 98 Thousand USD | 2621.429% |
| Singular Genomics Systems, Inc. | 59.05 Million USD | 104.184% |
| OraSure Technologies, Inc. | -276.9 Million USD | 99.108% |
| Pro-Dex, Inc. | 10.91 Million USD | 122.636% |
| Pulse Biosciences, Inc. | -35.22 Million USD | 92.984% |
| Predictive Oncology Inc. | -5.87 Million USD | 57.918% |
| Precision Optics Corporation, Inc. | 3.02 Million USD | 181.573% |
| QuidelOrtho Corporation | 2.49 Billion USD | 100.099% |
| Repligen Corporation | -39.51 Million USD | 93.747% |
| Sanara MedTech Inc. | 6.64 Million USD | 137.186% |
| STAAR Surgical Company | -147.2 Million USD | 98.321% |
| Sharps Technology, Inc. | -3.01 Million USD | 17.986% |
| Utah Medical Products, Inc. | -92.52 Million USD | 97.329% |
| DENTSPLY SIRONA Inc. | 1.96 Billion USD | 100.126% |
| Jin Medical International Ltd. | -2.81 Million USD | 12.267% |